A carregar...
Akt inhibitor MK-2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine
The PI3K/Akt pathway is an attractive therapeutic target in the treatment of pancreatic cancer, as it was demonstrated to be aberrantly regulated in pancreatic cancer cells. The present study aimed to investigate the therapeutic potential of the novel Akt inhibitor MK-2206 in human pancreatic cancer...
Na minha lista:
| Publicado no: | Oncol Lett |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7039141/ https://ncbi.nlm.nih.gov/pubmed/32194695 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2020.11300 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|